SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.

ABSTRACT:

Background

Prostate cancer (PC) is a commonly diagnosed malignancy in males, especially in the western hemisphere. The extensive use of multiple biomarkers plays an important role in the diagnosis and prognosis of PC. However, the accuracy of biomarkers for PC prognosis needs to be urgently improved. This study aimed to identify a novel prognostic biomarker for PC.

Materials and methods

Differentially methylated CpG sites were identified from the GSE76938 dataset ( https://www.ncbi.nlm.nih.gov/geo/ ) using R software version 3.1.4. Four significant CpG sites on the SLCO4C1 gene were found to be closely associated with prognosis in PC. Data downloaded from The Cancer Genome Atlas (TCGA) were used for validation. Co-expression and functional enrichment analyses were used to ex

SUBMITTER: Li X 

PROVIDER: S-EPMC6617673 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature